சில்வியா அவிலா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from சில்வியா அவிலா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In சில்வியா அவிலா Today - Breaking & Trending Today
Gustavo Bordet, el gobernador entrerriano de bajo perfil y con varios interrogantes turbios en el lomo agencianova.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from agencianova.com Daily Mail and Mail on Sunday newspapers.
Gustavo Bordet, el gobernador entrerriano de bajo perfil y con varios interrogantes turbios en el lomo agencianova.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from agencianova.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation. Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy January 7, 2021 GMT NEW YORK (BUSINESS WIRE) Jan 7, 2021 Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (DMD). The CIFFREO trial is expected to enroll 99 ambulatory male patients, ages 4 through 7, across 55 clinical trial sites in 15 countries. The first patient was dosed at a site in Barcelona, Spain on December 29, 2020. ....
Date Time Pfizer Doses First Participant in Phase 3 CIFFREO study NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (DMD). The CIFFREO trial is expected to enroll 99 ambulatory male patients, ages 4 through 7, across 55 clinical trial sites in 15 countries. The first patient was dosed at a site in Barcelona, Spain on December 29, 2020. CIFFREO is a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study. The primary endpoint of the study is the change from baseline in the North Star Ambulatory Assessment (NSAA) at one year. The NSAA is a 17-item test that measures gross motor function in boys with DMD. Regardless of cohort, eligible participants are scheduled to receive the investigational gene therapy, either at the s ....